摘要
目的:观察瑞舒伐他汀钙辅助氯吡格雷治疗急性冠脉综合征(ACS)的临床疗效.方法:选取2020年5月至2022年12月于本院心内科就诊治疗的ACS患者107例作为研究对象,根据药物方案不同分为实验组(n=55,瑞舒伐他汀钙辅助氯吡格雷治疗)和对照组(n=52,氯吡格雷治疗).比较两组总疗效、炎症反应与血管内皮功能[超敏C反应蛋白(hs-CRP)、白细胞介素(IL)-1、内皮素(ET)-1及一氧化氮(NO)]、心血管不良事件(MACE)发生率及用药安全性.结果:实验组总疗效率高于对照组,差异有统计学意义(P<0.05).实验组血清hs-CRP、IL-1及ET-1均显著低于对照组,NO水平高于对照组,差异均有统计学意义(P<0.05).实验组MACE总发生率(3.62%)显著低于对照组(17.30%),差异具有统计学意义(P<0.05).两组不良反应比较差异无统计学意义(P>0.05).结论:瑞舒伐他汀钙辅助氯吡格雷治疗ACS可提高其疗效,减少炎症因子生成,改善血管内皮功能,降低MACE发生率,且用药安全性高.
Objective:To observe the clinical efficacy of rosuvastatin calcium assisted clopidogrel in the treatment of acute coronary syndrome(ACS).Methods:A total of 107 patients with ACS who were treated in the cardiology department of our hospital from May 2020 to December 2022 were selected,and were divided into the experimental group(n=55,rosuvastatin calcium-assisted clopidogrel treatment)and the control group(n=52,clopidogrel treatment)according to different drug regimens.The overall efficacy,inflammatory response and vascular endothelial function[hypersensitive C-reactive protein(hs-CRP),interleukin(IL)-1,endothelin(ET)-land nitric oxide(NO)],major adverse cardiovascular events(MACE)and drug safety were compared between the two groups.Results:The total curative effect rate of experimental group was higher than that of reference group(P<0.05).Serum hs-CRP,IL-1 and ET-1 in test group were lower than those in reference group,and serum NO level in test group was higher than that in reference group,and the differences were statistically significant(P<0.05).The total incidence of MACE in test group(3.62%)was lower than that in reference group(17.30%),and the difference was statistically significant(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Rosuvastatin calcium assisted clopidogrel in the treatment of ACS can improve its efficacy,reduce the production of inflammatory factors,improve vascular endothelial function,and reduce the incidence of MACE,with high safety.
作者
刘虹
王迪
刘娜
LIU Hong;WANG Di;LIU Na(Department of Pharmacy,Suixian Traditional Chinese Medicine Hospital,Shangqiu 476900,China;Department of Seventh internal medicine,Suixian Traditional Chinese Medicine Hospital,Shangqiu 476900,China)
出处
《四川解剖学杂志》
2024年第1期73-76,共4页
Sichuan Journal of Anatomy
